Alliance Pharma plc (AIM: APH), the international healthcare group, has been notified that Andrew Franklin, the Chief Financial Officer of the Company, purchased 50,988 ordinary shares of 1.0p each in the Company ('Ordinary Shares') at a price of 49.005 pence per share on 18th July 2023 and Richard Jones, a non-executive Director of the Company, purchased 53,000 Ordinary Shares at a price of 47.10 pence per share on 18th July 2023.

Following this transaction, (i) Mr. Franklin's total beneficial interest in the Company is 179,372 Ordinary Shares, representing 0.03% of the Company's issued share capital and (ii) Mr. Jones' total beneficial interest in the Company is 68,000 Ordinary Shares, representing 0.013% of the Company's issued share capital.

Contact:

Tel: + 44 (0)20 7260 1000

About Alliance

Alliance Pharma plc (AIM: APH) is a growing consumer healthcare company. Our purpose is to empower people to make a positive difference to their health and wellbeing by making our trusted and proven brands available around the world.

We deliver organic growth through investing in our priority brands and channels, in related innovation, and through selective geographic expansion to increase the reach of our brands. Periodically, we may look to enhance our organic growth through selective, complementary acquisitions.

Headquartered in the UK, the Group employs around 285 people based in locations across Europe, North America, and the Asia Pacific region. By outsourcing our manufacturing and logistics we remain asset-light and focused on maximising the value we can bring, both to our stakeholders and to our brands.

(C) 2023 Electronic News Publishing, source ENP Newswire